Terms: = Kidney tumors AND GATA3, HDR, 2625, ENSG00000107485, MGC5445, MGC5199, MGC2346
103 results:
1. [Expression of programmed cell death ligand 1 and clinicopathological and immunological characteristics in fumarate hydratase-deficient renal cell carcinoma].
Chen S; Ban CR; Zhang XT; Chen YP; Ren CH; Chen H
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):155-161. PubMed ID: 38281783
[No Abstract] [Full Text] [Related]
2. Clear cell urothelial carcinoma of bladder: Case report of a rare and aggressive variant with review of literature.
Sahetia KM; Dave VN; Pal M; Menon S
Indian J Cancer; 2023 Oct; 60(4):575-577. PubMed ID: 38145907
[TBL] [Abstract] [Full Text] [Related]
3. Treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and Newborns.
Gougis P; Grandal B; Jochum F; Bihan K; Coussy F; Barraud S; Asselain B; Dumas E; Sebbag C; Hotton J; Spaggiari E; Pierga JY; Savarino R; Laas E; Spano JP; Reyal F; Hamy AS
JAMA Netw Open; 2023 Oct; 6(10):e2339934. PubMed ID: 37883083
[TBL] [Abstract] [Full Text] [Related]
4. Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT.
Ricci C; Ambrosi F; Franceschini T; Giunchi F; Grillini A; Franchini E; Grillini M; Schiavina R; Massari F; Mollica V; Tateo V; Bianchi FM; Bianchi L; Droghetti M; Maloberti T; Tallini G; Colecchia M; Acosta AM; Lobo J; Trpkov K; Fiorentino M; de Biase D
Virchows Arch; 2023 Nov; 483(5):687-698. PubMed ID: 37845471
[TBL] [Abstract] [Full Text] [Related]
5. Papillary renal neoplasm with reverse polarity: a clinicopathologic study of 43 cases with a focus on the expression of KRAS signaling pathway downstream effectors.
Kim B; Lee S; Moon KC
Hum Pathol; 2023 Dec; 142():1-6. PubMed ID: 37797754
[TBL] [Abstract] [Full Text] [Related]
6. Diagnostic Utility of gata3 and ISL1 in Differentiating Neuroblastoma From Other Pediatric Malignant Small Round Blue Cell tumors.
Mohanty SK; Diwaker P; Mishra SK; Jha S; Lobo A; Panda SP; Sharma S; Kumar M; Arora S; Mallik V; Jain D; Jain E; Chakrabarti I; Varshney J; Beg A; Dixit M; Baisakh MR; Naik S; Sahoo SK; Akgul M; Balzer BL; Amin MB; Parwani AV
Int J Surg Pathol; 2024 Apr; 32(2):294-303. PubMed ID: 37312579
[TBL] [Abstract] [Full Text] [Related]
7. Metastases to the kidney from primary lung cancer : clinicopathological analysis of six cases in a single center.
Lian H; Pan X; Hong B; Min J; Huang F
Diagn Pathol; 2023 May; 18(1):60. PubMed ID: 37161448
[TBL] [Abstract] [Full Text] [Related]
8. Diffuse Carbonic Anhydrase 9 and gata3 Expression in Fumarate Hydratase Deficient Renal Cell Carcinoma - A Case Report and Immunoprofile Review.
Pacheco RR; Pacheco R; Cooley C; Kaufman R; Akgul M
Int J Surg Pathol; 2024 Feb; 32(1):145-149. PubMed ID: 37050851
[TBL] [Abstract] [Full Text] [Related]
9. Expression profile and prognostic values of GATA family members in kidney renal clear cell carcinoma.
Yang X; Mei C; Nie H; Zhou J; Ou C; He X
Aging (Albany NY); 2023 Mar; 15(6):2170-2188. PubMed ID: 36961416
[TBL] [Abstract] [Full Text] [Related]
10. Low-grade oncocytic tumour (LOT) of the kidney is characterised by gata3 positivity, FOXI1 negativity and mTOR pathway mutations.
Chen T; Peng Y; Lei T; Wu C; Wang H; Shi Y
Pathol Oncol Res; 2023; 29():1610852. PubMed ID: 36816543
[No Abstract] [Full Text] [Related]
11. Papillary renal cell neoplasm with reverse polarity: A new subtype of renal tumour with favorable prognosis.
Conde-Ferreirós M; Domínguez-de Dios J; Juaneda-Magdalena L; Bellas-Pereira A; San Miguel Fraile MP; Peteiro Cancelo MÁ; Gómez-de María C; Álvarez Sarria M; Betancor Santos MÁ; González-Carreró J; Ortiz-Rey JA
Actas Urol Esp (Engl Ed); 2022 Dec; 46(10):600-605. PubMed ID: 36216763
[TBL] [Abstract] [Full Text] [Related]
12. Low-grade oncocytic tumour of the kidney is characterised by genetic alterations of TSC1, TSC2, MTOR or PIK3CA and consistent gata3 positivity.
Williamson SR; Hes O; Trpkov K; Aggarwal A; Satapathy A; Mishra S; Sharma S; Sangoi A; Cheng L; Akgul M; Idrees M; Levin A; Sadasivan S; San Miguel Fraile P; Rogala J; Comperat E; Berney DM; Bulimbasic S; McKenney JK; Jha S; Sampat NY; Mohanty SK
Histopathology; 2023 Jan; 82(2):296-304. PubMed ID: 36208048
[TBL] [Abstract] [Full Text] [Related]
13. Papillary Renal Neoplasm With Reverse Polarity: A Clinical, Pathologic, and Molecular Study of 8 Renal tumors From a Single Institution.
Nova-Camacho LM; Martin-Arruti M; Díaz IR; Panizo-Santos Á
Arch Pathol Lab Med; 2023 Jun; 147(6):692-700. PubMed ID: 36170616
[TBL] [Abstract] [Full Text] [Related]
14. Algorithm-Based Approach to the Histological Routine Diagnosis of Renal Oncocytic tumors in Core Biopsy Specimens.
Manini C; Imaz I; de Larrinoa AF; López JI
Curr Urol Rep; 2022 Nov; 23(11):327-333. PubMed ID: 36169870
[TBL] [Abstract] [Full Text] [Related]
15. Papillary renal neoplasm with reverse polarity may be a novel renal cell tumor entity with low malignant potential.
Yang T; Kang E; Zhang L; Zhuang J; Li Y; Jiang Y; Wang H; Yu W; Zhang W
Diagn Pathol; 2022 Aug; 17(1):66. PubMed ID: 36002896
[TBL] [Abstract] [Full Text] [Related]
16. TFE3 and TFEB-rearranged renal cell carcinomas: an immunohistochemical panel to differentiate from common renal cell neoplasms.
Caliò A; Marletta S; Brunelli M; Pedron S; Portillo SC; Segala D; Bariani E; Gobbo S; Netto G; Martignoni G
Virchows Arch; 2022 Dec; 481(6):877-891. PubMed ID: 35980471
[TBL] [Abstract] [Full Text] [Related]
17. Papillary renal neoplasm with reverse polarity-a comparative study with CCPRCC, OPRCC, and PRCC1.
Wang T; Ding X; Huang X; Ye J; Li H; Cao S; Gao Y; Ma X; Huang Q; Wang B
Hum Pathol; 2022 Nov; 129():60-70. PubMed ID: 35977593
[TBL] [Abstract] [Full Text] [Related]
18. EUS-guided fine needle aspiration provides an open view for duodenal obstruction caused by urothelial carcinoma: a case report.
Chen X; Chen X; Yu X; He X
BMC Gastroenterol; 2022 Aug; 22(1):376. PubMed ID: 35941530
[TBL] [Abstract] [Full Text] [Related]
19. Immunohistochemical expression of renin and gata3 help distinguish juxtaglomerular cell tumors from renal glomus tumors.
Gupta S; Folpe AL; Torres-Mora J; Reuter VE; Zuckerman JE; Falk N; Stanton ML; Muthusamy S; Smith SC; Sharma V; Sethi S; Herrera-Hernandez L; Jimenez RE; Cheville JC
Hum Pathol; 2022 Oct; 128():110-123. PubMed ID: 35926808
[TBL] [Abstract] [Full Text] [Related]
20. gata3 aids in distinguishing fumarate hydratase-deficient renal cell carcinoma from papillary renal cell carcinoma.
Liu Y; Dong Y; Gu Y; Xu H; Fan Y; Li X; Dong L; Zhou L; Yang X; Wang C
Ann Diagn Pathol; 2022 Oct; 60():152007. PubMed ID: 35841867
[TBL] [Abstract] [Full Text] [Related]
[Next]
